Amphastar Pharmaceuticals, INC 8-K filings

Amphastar Pharmaceuticals announced its financial results for the second quarter of 2026, reporting net revenues of $183.9 million and GAAP net income of $30.3 million.

Amphastar Pharmaceuticals reported mixed Q1 2026 results, with flat net revenues but a significant drop in GAAP net income and adjusted non-GAAP net income, alongside increased R&D spending.

Amphastar Pharmaceuticals' Board of Directors authorized a $50 million increase to its share buyback program to offset equity compensation dilution.

Amphastar Pharmaceuticals, Inc. announced new executive employment agreements for Jacob Liawatidewi and Rong Zhou, detailing compensation, severance, and change-in-control provisions.

Amphastar Pharmaceuticals, Inc. disclosed new and amended agreements with related parties for chemical intermediates supply and research services, involving family members of its top executives.

Amphastar Pharmaceuticals announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, highlighting BAQSIMI's continued growth and new product approvals amidst overall revenue decline.

Amphastar Pharmaceuticals announced an exclusive licensing agreement with Nanjing Hanxin for AMP-110, a synthetic corticotropin compound targeting inflammatory and autoimmune conditions, involving an upfront payment and significant milestone opportunities.

Amphastar Pharmaceuticals reported Q3 2025 net revenues of $191.8 million, flat year-over-year, with GAAP net income significantly impacted by a $23.1 million litigation provision.

Amphastar Pharmaceuticals has entered a 10-year exclusive distribution agreement with Nanjing Chengong Pharmaceutical to market BAQSIMI in Greater China.

Amphastar Pharmaceuticals, Inc. signed a three-year, $2.8 million contract research agreement with related-party Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for the development of Recombinant Peptide Research Cell Banks for its AMP-107 product candidate.

Amphastar Pharmaceuticals secures exclusive license for three proprietary peptide products from Nanjing Anji Biotechnology, targeting oncology and ophthalmology.

Amphastar Pharmaceuticals reported a 4% decrease in Q2 2025 net revenues to $174.4 million, driven by strong BAQSIMI sales growth and a strategic plan to quadruple U.S. manufacturing capacity.

Amphastar Pharmaceuticals, Inc. announced the expansion of its Board of Directors from ten to eleven members and the immediate appointment of David Gaugh as an independent Class I director.

Amphastar Pharmaceuticals, Inc. announced that its stockholders approved significant amendments to its corporate charter and bylaws, including officer exculpation and revised forum selection provisions, alongside the election of three Class III directors and ratification of its independent auditor.

Amphastar Pharmaceuticals announces its financial results for the three months ended March 31, 2025, reporting net revenues of $170.5 million.

Amphastar Pharmaceuticals announces positive financial results for the three months and full year ended December 31, 2024, with net revenues reaching $186.5 million for the quarter and $732.0 million for the year.

Amphastar Pharmaceuticals announced its third-quarter 2024 financial results, highlighting revenue growth driven by strong sales of BAQSIMI and Primatene MIST.

Amphastar Pharmaceuticals' subsidiary, Armstrong, has entered into a 10-year exclusive distribution agreement with Genreach for Primatene MIST in Greater China, with estimated revenue of $10 million.

Amphastar Pharmaceuticals announced a robust second quarter with net revenues of $182.4 million, driven by strong sales of BAQSIMI and other key products.

Amphastar Pharmaceuticals has increased its share buyback program by $50 million and approved an amended equity incentive plan at its 2024 annual meeting.

Amphastar Pharmaceuticals announced a robust first quarter with a 23% increase in net revenues, driven by a 22% growth in BAQSIMI sales compared to the previous year.

Amphastar Pharmaceuticals announced robust financial results for the fourth quarter and full year of 2023, highlighted by significant revenue growth and increased profitability.